Cargando…

Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies

Necrotizing autoimmune myopathy (NAM) is a rare muscular disorder characterized by severe proximal muscle weakness. Risk factors include statin use, malignancy, and connective tissue diseases. The current study presents the first case of NAM in Saudi Arabia in a 26-year-old female who presented with...

Descripción completa

Detalles Bibliográficos
Autores principales: Almaghrabi, Murouj, Almatrafi, Shahad B, Alzahrani, Asma, Alharbi, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043635/
https://www.ncbi.nlm.nih.gov/pubmed/36999097
http://dx.doi.org/10.7759/cureus.35471
_version_ 1784913194767089664
author Almaghrabi, Murouj
Almatrafi, Shahad B
Alzahrani, Asma
Alharbi, Mohammed
author_facet Almaghrabi, Murouj
Almatrafi, Shahad B
Alzahrani, Asma
Alharbi, Mohammed
author_sort Almaghrabi, Murouj
collection PubMed
description Necrotizing autoimmune myopathy (NAM) is a rare muscular disorder characterized by severe proximal muscle weakness. Risk factors include statin use, malignancy, and connective tissue diseases. The current study presents the first case of NAM in Saudi Arabia in a 26-year-old female who presented with proximal upper and lower limb weakness, dysphagia, dysarthria, and dyspnea with no previous medical or surgical history and was not on medication. Targeted myopathic antibody analysis revealed antibodies to signal recognition particles (SRP), and the serum creatinine kinase level reached 9308 U/L. A diagnosis of NAM was made, and the patient was started on the management plan. We discussed an interesting case progression and adverse effect challenges, as well as the management of these difficult-to-treat conditions.
format Online
Article
Text
id pubmed-10043635
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-100436352023-03-29 Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies Almaghrabi, Murouj Almatrafi, Shahad B Alzahrani, Asma Alharbi, Mohammed Cureus Internal Medicine Necrotizing autoimmune myopathy (NAM) is a rare muscular disorder characterized by severe proximal muscle weakness. Risk factors include statin use, malignancy, and connective tissue diseases. The current study presents the first case of NAM in Saudi Arabia in a 26-year-old female who presented with proximal upper and lower limb weakness, dysphagia, dysarthria, and dyspnea with no previous medical or surgical history and was not on medication. Targeted myopathic antibody analysis revealed antibodies to signal recognition particles (SRP), and the serum creatinine kinase level reached 9308 U/L. A diagnosis of NAM was made, and the patient was started on the management plan. We discussed an interesting case progression and adverse effect challenges, as well as the management of these difficult-to-treat conditions. Cureus 2023-02-25 /pmc/articles/PMC10043635/ /pubmed/36999097 http://dx.doi.org/10.7759/cureus.35471 Text en Copyright © 2023, Almaghrabi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Almaghrabi, Murouj
Almatrafi, Shahad B
Alzahrani, Asma
Alharbi, Mohammed
Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies
title Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies
title_full Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies
title_fullStr Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies
title_full_unstemmed Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies
title_short Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies
title_sort marked efficacy of a therapeutic strategy in a patient with necrotizing myopathy associated with anti-signal recognition particle (srp) autoantibodies
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043635/
https://www.ncbi.nlm.nih.gov/pubmed/36999097
http://dx.doi.org/10.7759/cureus.35471
work_keys_str_mv AT almaghrabimurouj markedefficacyofatherapeuticstrategyinapatientwithnecrotizingmyopathyassociatedwithantisignalrecognitionparticlesrpautoantibodies
AT almatrafishahadb markedefficacyofatherapeuticstrategyinapatientwithnecrotizingmyopathyassociatedwithantisignalrecognitionparticlesrpautoantibodies
AT alzahraniasma markedefficacyofatherapeuticstrategyinapatientwithnecrotizingmyopathyassociatedwithantisignalrecognitionparticlesrpautoantibodies
AT alharbimohammed markedefficacyofatherapeuticstrategyinapatientwithnecrotizingmyopathyassociatedwithantisignalrecognitionparticlesrpautoantibodies